Cargando…

Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer

Only a few papers have been published concerning the incidence and outcome of patients with a pathological complete response after cytotoxic treatment in breast cancer. The purpose of this retrospective study was to assess the outcome of patients found to have a pathological complete response in bot...

Descripción completa

Detalles Bibliográficos
Autores principales: Chollet, P, Amat, S, Cure, H, de Latour, M, Bouedec, G Le, Mouret-Reynier, M-A, Ferriere, J-P, Achard, J-L, Dauplat, J, Penault-Llorca, F
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364175/
https://www.ncbi.nlm.nih.gov/pubmed/11953845
http://dx.doi.org/10.1038/sj.bjc.6600210
_version_ 1782153887891849216
author Chollet, P
Amat, S
Cure, H
de Latour, M
Bouedec, G Le
Mouret-Reynier, M-A
Ferriere, J-P
Achard, J-L
Dauplat, J
Penault-Llorca, F
author_facet Chollet, P
Amat, S
Cure, H
de Latour, M
Bouedec, G Le
Mouret-Reynier, M-A
Ferriere, J-P
Achard, J-L
Dauplat, J
Penault-Llorca, F
author_sort Chollet, P
collection PubMed
description Only a few papers have been published concerning the incidence and outcome of patients with a pathological complete response after cytotoxic treatment in breast cancer. The purpose of this retrospective study was to assess the outcome of patients found to have a pathological complete response in both the breast and axillary lymph nodes after neoadjuvant chemotherapy for operable breast cancer. Our goal was also to determine whether the residual pathological size of the tumour in breast could be correlated with pathological node status. Between 1982 and 2000, 451 consecutive patients were registered into five prospective phase II trials. After six cycles, 396 patients underwent surgery with axillary dissection for 277 patients (69.9%). Pathological response was evaluated according to the Chevallier's classification. At a median follow-up of 8 years, survival was analysed as a function of pathological response. A pathological complete response rate was obtained in 60 patients (15.2%) after induction chemotherapy. Breast tumour persistence was significantly related to positive axillary nodes (P=5.10(−6)). At 15 years, overall survival and disease-free survival rates were significantly higher in the group who had a pathological complete response than in the group who had less than a pathological complete response (P=0.047 and P=0.024, respectively). In the absence of pathological complete response and furthermore when there is a notable remaining pathological disease, axillary dissection is still important to determine a major prognostic factor and subsequently, a second non cross resistant adjuvant regimen or high dose chemotherapy could lead to a survival benefit. British Journal of Cancer (2002) 86, 1041–1046. DOI: 10.1038/sj/bjc/6600210 www.bjcancer.com © 2002 Cancer Research UK
format Text
id pubmed-2364175
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23641752009-09-10 Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer Chollet, P Amat, S Cure, H de Latour, M Bouedec, G Le Mouret-Reynier, M-A Ferriere, J-P Achard, J-L Dauplat, J Penault-Llorca, F Br J Cancer Clinical Only a few papers have been published concerning the incidence and outcome of patients with a pathological complete response after cytotoxic treatment in breast cancer. The purpose of this retrospective study was to assess the outcome of patients found to have a pathological complete response in both the breast and axillary lymph nodes after neoadjuvant chemotherapy for operable breast cancer. Our goal was also to determine whether the residual pathological size of the tumour in breast could be correlated with pathological node status. Between 1982 and 2000, 451 consecutive patients were registered into five prospective phase II trials. After six cycles, 396 patients underwent surgery with axillary dissection for 277 patients (69.9%). Pathological response was evaluated according to the Chevallier's classification. At a median follow-up of 8 years, survival was analysed as a function of pathological response. A pathological complete response rate was obtained in 60 patients (15.2%) after induction chemotherapy. Breast tumour persistence was significantly related to positive axillary nodes (P=5.10(−6)). At 15 years, overall survival and disease-free survival rates were significantly higher in the group who had a pathological complete response than in the group who had less than a pathological complete response (P=0.047 and P=0.024, respectively). In the absence of pathological complete response and furthermore when there is a notable remaining pathological disease, axillary dissection is still important to determine a major prognostic factor and subsequently, a second non cross resistant adjuvant regimen or high dose chemotherapy could lead to a survival benefit. British Journal of Cancer (2002) 86, 1041–1046. DOI: 10.1038/sj/bjc/6600210 www.bjcancer.com © 2002 Cancer Research UK Nature Publishing Group 2002-04-08 /pmc/articles/PMC2364175/ /pubmed/11953845 http://dx.doi.org/10.1038/sj.bjc.6600210 Text en Copyright © 2002 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
Chollet, P
Amat, S
Cure, H
de Latour, M
Bouedec, G Le
Mouret-Reynier, M-A
Ferriere, J-P
Achard, J-L
Dauplat, J
Penault-Llorca, F
Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer
title Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer
title_full Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer
title_fullStr Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer
title_full_unstemmed Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer
title_short Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer
title_sort prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364175/
https://www.ncbi.nlm.nih.gov/pubmed/11953845
http://dx.doi.org/10.1038/sj.bjc.6600210
work_keys_str_mv AT cholletp prognosticsignificanceofacompletepathologicalresponseafterinductionchemotherapyinoperablebreastcancer
AT amats prognosticsignificanceofacompletepathologicalresponseafterinductionchemotherapyinoperablebreastcancer
AT cureh prognosticsignificanceofacompletepathologicalresponseafterinductionchemotherapyinoperablebreastcancer
AT delatourm prognosticsignificanceofacompletepathologicalresponseafterinductionchemotherapyinoperablebreastcancer
AT bouedecgle prognosticsignificanceofacompletepathologicalresponseafterinductionchemotherapyinoperablebreastcancer
AT mouretreynierma prognosticsignificanceofacompletepathologicalresponseafterinductionchemotherapyinoperablebreastcancer
AT ferrierejp prognosticsignificanceofacompletepathologicalresponseafterinductionchemotherapyinoperablebreastcancer
AT achardjl prognosticsignificanceofacompletepathologicalresponseafterinductionchemotherapyinoperablebreastcancer
AT dauplatj prognosticsignificanceofacompletepathologicalresponseafterinductionchemotherapyinoperablebreastcancer
AT penaultllorcaf prognosticsignificanceofacompletepathologicalresponseafterinductionchemotherapyinoperablebreastcancer